The Journal of Heart and Lung Transplantation
Volume 27, Issue 12 , Pages 1311-1318 , December 2008

Proliferation Signal Inhibitor–induced Decrease of Vascular Endothelial Cadherin Expression and Increase of Endothelial Permeability In Vitro Are Prevented by an Anti-oxidant

Received 24 April 2008 ,Revised 19 August 2008 ,Accepted 26 August 2008.

References 

  1. Morris RE. Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action. Ann NY Acad Sci. 1995;685:68–72
  2. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335–340
  3. Morris RE. Immunopharmacology of new xenobiotic immunosuppressive molecules. Semin Nephrol. 1992;12:304–314
  4. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant. 2008;27:141–149
  5. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007. J Heart Lung Transplant. 2007;26:769–781
  6. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? (Lessons learned from renal transplantation and oncology). J Heart Lung Transplant. 2007;26:557–564
  7. De Meester JM, Van Vlem B, Walravens M, et al. Preservation of renal function after heart transplantation: initial single-center experience with sirolimus. Transplant Proc. 2005;37:1835–1838
  8. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev. 2006;20:1–18
  9. Fuchs U, Zittermann A, Berthold HK, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation. 2005;79:981–983
  10. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation. 2001;72:162–164
  11. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84:869–901
  12. Lampugnani MG, Resnati M, Raiteri M, et al. A novel endothelial-specific membrane protein is a marker of cell–cell contacts. J Cell Biol. 1992;118:1511–1522
  13. Nwariaku FE, Liu Z, Zhu X, et al. Tyrosine phosphorylation of vascular endothelial cadherin and the regulation of microvascular permeability. Surgery. 2002;132:180–185
  14. Friedl J, Puhlmann M, Bartlett DL, et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood. 2002;100:1334–1339
  15. Puhlmann M, Weinreich DM, Farma JM, et al. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transplant Med. 2005;3:37
  16. Friedl J, Turner E, Alexander HR. Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: evidence for disruption of vascular integrity via VE-cadherin down-regulation. Int J Oncol. 2003;23:611–616
  17. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223–1234
  18. Zhang Y, Zhao S, Gu Y, et al. Effects of peroxynitrite and superoxide radicals on endothelial monolayer permeability: potential role of peroxynitrite in preeclampsia. J Soc Gynecol Invest. 2005;12:586–592
  19. Zhang Y, Gu Y, Lucas MJ, Wang Y. Antioxidant superoxide dismutase attenuates increased endothelial permeability induced by platelet-activating factor. J Soc Gynecol Invest. 2003;10:5–10
  20. Wang Y, Gu Y, Granger DN, Roberts JM, Alexander JS. Endothelial junctional protein redistribution and increased monolayer permeability in human umbilical vein endothelial cells isolated during preeclampsia. Am J Obstet Gynecol. 2002;186:214–220
  21. Park J, Ha H, Kim MS, et al. Carvedilol inhibits platelet-derived growth factor-induced extracellular matrix synthesis by inhibiting cellular reactive oxygen species and mitogen-activated protein kinase activation. J Heart Lung Transplant. 2006;25:683–689
  22. Radovits T, Lin LN, Zotkina J, et al. Endothelial dysfunction after long-term cold storage in HTK organ preservation solutions: effects of iron chelators and N-alpha-acetyl-l-histidine. J Heart Lung Transplant. 2008;27:208–216
  23. Trapp A, Weis M. The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol. 2005;45:81–87
  24. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins (Identification by morphologic and immunologic criteria). J Clin Invest. 1973;52:2745–2756
  25. Oroszlan M, Herczenik E, Rugonfalvi-Kiss S, et al. Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP. Int Immunol. 2006;18:871–878
  26. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res. 2005;68:26–36
  27. Noronha-Dutra AA, Epperlein MM, Woolf N. Reaction of nitric oxide with hydrogen peroxide to produce potentially cytotoxic singlet oxygen as a model for nitric oxide-mediated killing. FEBS Lett. 1993;321:59–62
  28. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990;87:1620–1624
  29. Navarro-Antolin J, Redondo-Horcajo M, Zaragoza C, et al. Role of peroxynitrite in endothelial damage mediated by cyclosporine A. Free Rad Biol Med. 2007;42:394–403
  30. Wilasrusmee C, Da Silva M, Singh B, et al. Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction. Clin Transplant. 2003;17(suppl 9):6–12
  31. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA. 2004;101:9463–9467
  32. Morris RE. Rapamycin: FK506's fraternal twin or distant cousin?. Immunol Today. 1991;12:137–140
  33. Nickel T, Schlichting CL, Weis M. Drugs modulating endothelial function after transplantation. Transplantation. 2006;82(suppl):S41–S46
  34. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758

 Supported by the Katharina Huber-Steiner Foundation, Bern, Switzerland.

PII: S1053-2498(08)00643-8

doi: 10.1016/j.healun.2008.08.013

The Journal of Heart and Lung Transplantation
Volume 27, Issue 12 , Pages 1311-1318 , December 2008

Article Tools

* Image Usage & Resolution